GRPR and neoplasm: It was previously demonstrated that, as targeting agents, GRPR antagonists are superior to GRPR agonists because of the former’s higher number of binding sites, higher metabolic stability, or stronger interaction with the receptor, which explains the continuous tumor retention over time (29).